Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus

Matsumoto, Kazunari; Fujita, Naruhiro; Nakamura, K.; Senoo, Takemasa; Tominaga, Tan; Ueki, Yukitaka

doi:10.1016/j.diabres.2008.06.018

Cited by 10 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in people with non-genotype 3 HCV, hepatosteatosis is primarily related to the host factors of obesity, insulin resistance and DM, and antiviral therapy does not ameliorate steatosis in these patients [ 26 ]. Established studies [ 28 , 29 , 30 ] showed higher ApoB levels or ApoB/AI ratios associated with fatty liver in patients with DM and in and the general population. Greater ApoB expression is associated with insulin resistance [ 31 ], and delayed ApoB clearance is associated with triglyceride lipolysis, greater oxidative stress, and greater glycosylation oxidization of lipoprotein particles [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study

Lin

Guo²,

Lin³

et al. 2016

Obes Facts

View full text Add to dashboard Cite

Objective: Non-alcoholic fatty liver disease (NAFLD) is an established risk factor for diabetes, cardiovascular disease, antiviral treatment resistance, and progression of chronic hepatitis C virus (HCV) infection to fibrosis. Apolipoprotein-B 100 (ApoB-100) is a dyslipidemia marker and steatosis predictor. We assess the correlation between ApoB-100 and hepatosteatosis. Methods: This cross-sectional study enrolled 1,218 HCV-seropositive participants from a 2012-2013 health checkup in Taiwan. NAFLD was detected using ultrasound. All anthropometric and laboratory studies that included ApoB-100 were evaluated whether or not ApoB-100 predicts NAFLD. Logistic regression was also used to examine the association between ApoB-100 and NAFLD. Results: Participants were 47.16 ± 16.08 years old (mean age). The overall prevalence of NAFLD was 35.8% (n = 436; 32.8% men, 38.1% women). Participants with ApoB-100 ≥ 8 had a significantly higher incidence of NAFLD (39.4 vs. 29.4%; 95% CI 0.044-0.156; p < 0.001). After confounding factors had been adjusted for, ApoB-100 was significantly associated with NAFLD (OR 5.45; 95% CI 1.64-18.06; p = 0.006) and high-grade hepatosteatosis (OR 7.73; 95% CI 1.74-34.35; p = 0.007). Conclusion: ApoB-100 is strongly associated with NAFLD in people with non-genotype 3 HCV; greater ApoB-100 content is significantly correlated with higher-grade hepatosteatosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study

Lin

Guo²,

Lin³

et al. 2016

Obes Facts

View full text Add to dashboard Cite

show abstract

“…Concentrations of apolipoprotein B have also been shown to be associated with diabetic retinopathy [33], microalbumiuria [34,35], carotid atherosclerosis [36,37], and coronary artery calcification [38]. Thus, the drop in mean concentration of apolipoprotein B in adults with diabetes in the present study, which was consistent with the decreases in mean concentrations of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, suggests a lessening of cardiovascular risk among people with diabetes.…”

Section: Discussionmentioning

confidence: 99%

Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988--1991 to 2005--2008

Ford

Sniderman

2013

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundDiabetes is characterized by profound lipid abnormalities. The objective of this study was to examine changes in concentrations of lipids and apolipoprotein B among participants stratified by glycemic status (diabetes, undiagnosed diabetes, prediabetes, and normoglycemia) in the United States from 1988–1991 to 2005–2008.MethodsWe used data from 3202 participants aged ≥20 years from the National Health and Nutrition Examination Survey (NHANES) III (1988–1991) and 3949 participants aged ≥20 years from NHANES 2005–2008.ResultsAmong participants of all four groups, unadjusted and adjusted mean concentrations of total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B, but not triglycerides, decreased significantly. Among participants with prediabetes and normoglycemia, unadjusted and adjusted mean concentrations of high-density lipoprotein cholesterol increased significantly. Adjusted mean log-transformed concentrations of triglycerides decreased in adults with undiagnosed diabetes and prediabetes. During 2005–2008, unadjusted concentrations of apolipoprotein B ≥80 mg/dl were observed in 72.8% of participants with diagnosed diabetes, 87.9% of participants with undiagnosed diabetes, 86.6% of participants with prediabetes, and 77.2% of participants with normoglycemia. The unadjusted use of cholesterol-lowering medications rose rapidly, especially among participants with diabetes (from ~1% to ~49%, P <0.001). The use of fenofibrate, gemfibrozil, and niacin rose significantly only among adults with diagnosed diabetes (from ~2% to ~8%, P = 0.011).ConclusionLipid profiles of adults with diabetes improved during the approximately 16-year study period. Nevertheless, large percentages of adults continue to have elevated concentrations of apolipoprotein B.

show abstract

“…These initial abnormalities appear to lead to hepatic and intestinal overproduction of highly atherogenic lipoprotein particles that result in the commonly observed phenotype of hypertirglyceridemia, hyperapolipoprotein B, low levels of high density lipoprotein-cholesterol (HDL-C) [ 5 ]. Even though low density lipoprotein cholesterol (LDL-C) is known as an established risk factor for atherosclerosis [ 6 ], many of recent studies reported that apolipoprotein B (ApoB) is a better measure of cardiovascular disease (CVD) risk than LDL-C [ 6 7 8 9 10 ], because ApoB indicates the number of potentially atherogenic lipoprotein particles [ 11 ]. Emerging evidences have demonstrated that ApoB may be a significant predictor of CVD risk in subjects carrying metabolic syndrome (MetS), which is consistent with the reports from multiple studies performed in populations with MetS or its features, which also demonstrate the ApoB-associated risk [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Association of Serum Apolipoprotein B with the Increased Risk of Diabetes in Korean Men

Lim

Kim

2016

Clin Nutr Res

View full text Add to dashboard Cite

This study aimed to investigate the association of Apolipoprotein B (ApoB) with the risk of diabetes in Koreans. Korean men (n = 790, 40-79 years) who had been never diagnosed for diabetes before participating were enrolled. Subjects were categorized into normal fasting glucose (NFG, n = 519), impaired fasting glucose (IFG, n = 188) and newly-onset diabetes (n = 83) according to fasting glucose levels. Age was not significantly different among the subgroups. Mean values of BMI, waist circumference, Blood pressure(BP), triglyceride, non-HDL cholesterol were significantly higher in IFG or newly-onset diabetic subjects compared to NFG subjects. The levels of glucose, insulin, free fatty acid, insulin resistance and ApoB were highest in diabetic patients and lowest in NFG subjects. According to ApoB level, subjects were divided into two groups (high-ApoB group: ≥ 87.0 mg/dL vs. low-ApoB group: < 87.0 mg/dL). The risk of diabetes was higher in the high-ApoB group than the low-ApoB group [OR0: 2.392, (95% CI: 1.470-3.893), P0 < 0.001]. This association was maintained after adjusted for age and BMI [OR1: 2.228, (95% CI: 1.362-3.646), P1 = 0.001] and further adjustment for blood pressure, triglyceride, HDL-cholesterol, LDL-cholesterol, non-HDL-cholesterol, ApoA1 and adiponectin [OR2: 1.984, (95% CI: 1.001-4.064), P2 = 0.049]. The association was much greater in subjects with metabolic syndrome (MetS) [OR1: 2.805 (95% CI: 1.137-5.737), P1 = 0.005] than in those without [OR1: 1.917 (95% CI: 0.989-3.718), P1 = 0.054]. After 3-month, further investigation was randomly performed in subjects with NFG or IFG who agreed to reinvestigation. Multiple stepwise regression analysis revealed that net change of ApoB levels was a main contributor to the net change of glucose levels (standardized b-coefficient: 0.315, p = 0.002). In conclusion, ApoB levels are closely associated with the increased risk of diabetes in Korean men.

show abstract

Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus

Cited by 10 publications

References 25 publications

Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study

Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study

Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988--1991 to 2005--2008

Association of Serum Apolipoprotein B with the Increased Risk of Diabetes in Korean Men

Contact Info

Product

Resources

About